German pharma industry unveils plan to address drug shortages

20 January 2025

Germany’s pharmaceutical sector is taking steps to combat worsening drug supply shortages, which have been driven by production bottlenecks, global dependencies, and increasing demand.

In recent periods, drug shortages in Germany have been particularly acute during times of geopolitical tensions and global crises like the COVID-19 pandemic.

The shortages, which affect both everyday and innovative medicines, are a particular concern for the German pharma industry’s leading trade body, the Association of Research-Based Pharmaceutical Companies (VFA).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical